Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas

BACKGROUND: The phase 2 REGOMA trial suggested an encouraging overall survival benefit in glioblastoma patients at first relapse treated with the multikinase inhibitor regorafenib. Here, we evaluated the efficacy and side effects of regorafenib in a real-life setting. METHODS: From 2018 to 2021, 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Jan-Michael, Wolf, Lena, Tscherpel, Caroline, Bauer, Elena K., Wollring, Michael, Ceccon, Garry, Deckert, Martina, Brunn, Anna, Pappesch, Roberto, Goldbrunner, Roland, Fink, Gereon R., Galldiks, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424167/
https://www.ncbi.nlm.nih.gov/pubmed/35716310
http://dx.doi.org/10.1007/s11060-022-04066-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424167/
https://www.ncbi.nlm.nih.gov/pubmed/35716310
http://dx.doi.org/10.1007/s11060-022-04066-9

Ejemplares similares